ECSP034848A - Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes - Google Patents

Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes

Info

Publication number
ECSP034848A
ECSP034848A EC2003004848A ECSP034848A ECSP034848A EC SP034848 A ECSP034848 A EC SP034848A EC 2003004848 A EC2003004848 A EC 2003004848A EC SP034848 A ECSP034848 A EC SP034848A EC SP034848 A ECSP034848 A EC SP034848A
Authority
EC
Ecuador
Prior art keywords
diabetes
treatment
ppar
oxazol
alpha
Prior art date
Application number
EC2003004848A
Other languages
English (en)
Spanish (es)
Inventor
Markus Boehringer
Markus Meyer
Peter Mohr
Hanspeter Hilpert
Alfred Binggeli
Hans Peter Maerki
Fabienne Ricklin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP034848A publication Critical patent/ECSP034848A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EC2003004848A 2001-05-15 2003-11-13 Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes ECSP034848A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15

Publications (1)

Publication Number Publication Date
ECSP034848A true ECSP034848A (es) 2003-12-24

Family

ID=8177436

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004848A ECSP034848A (es) 2001-05-15 2003-11-13 Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes

Country Status (38)

Country Link
US (1) US6642389B2 (enExample)
EP (1) EP1392295B1 (enExample)
JP (2) JP4330883B2 (enExample)
KR (1) KR100654516B1 (enExample)
CN (1) CN100356917C (enExample)
AR (1) AR035892A1 (enExample)
AT (1) ATE327753T1 (enExample)
AU (1) AU2002342244B2 (enExample)
BG (1) BG66316B1 (enExample)
BR (1) BRPI0209821B1 (enExample)
CA (1) CA2445145C (enExample)
CY (1) CY1105160T1 (enExample)
CZ (1) CZ20033037A3 (enExample)
DE (1) DE60211891T2 (enExample)
DK (1) DK1392295T3 (enExample)
EC (1) ECSP034848A (enExample)
EG (1) EG25755A (enExample)
ES (1) ES2264482T3 (enExample)
GT (1) GT200200085A (enExample)
HR (1) HRP20030889B1 (enExample)
HU (1) HU230224B1 (enExample)
IL (2) IL158589A0 (enExample)
JO (1) JO2282B1 (enExample)
MA (1) MA27025A1 (enExample)
ME (1) ME01310B (enExample)
MX (1) MXPA03010435A (enExample)
MY (1) MY136761A (enExample)
NO (1) NO333833B1 (enExample)
NZ (1) NZ529033A (enExample)
PA (1) PA8544901A1 (enExample)
PE (1) PE20021152A1 (enExample)
PL (1) PL208074B1 (enExample)
PT (1) PT1392295E (enExample)
RU (1) RU2278859C2 (enExample)
SI (1) SI1392295T1 (enExample)
SK (1) SK287842B6 (enExample)
WO (1) WO2002092084A1 (enExample)
ZA (1) ZA200308538B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
IL152979A0 (en) * 2000-05-26 2003-06-24 Nippon Shinyaku Co Ltd Heterocyclic compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7259175B2 (en) 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
ATE483699T1 (de) * 2002-08-30 2010-10-15 Hoffmann La Roche Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
JP2006514976A (ja) * 2002-11-15 2006-05-18 カディラ ヘルスケア リミティド 置換されているアラルキル誘導体
DE60323130D1 (de) * 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7262303B2 (en) 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
RU2374230C2 (ru) 2003-11-05 2009-11-27 Ф.Хоффманн-Ля Рош Аг Фенильные производные в качестве ppar агонистов
KR100849352B1 (ko) 2003-11-05 2008-07-29 에프. 호프만-라 로슈 아게 Ｐｐａｒ 활성화제로서 벤조-융합된 화합물
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
MXPA06012683A (es) 2004-05-03 2007-01-16 Hoffmann La Roche Derivados de indolilo como moduladores de receptor x del higado.
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
US20100063041A1 (en) * 2007-03-07 2010-03-11 Ho-Sang Moon Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
ES2390620T3 (es) * 2008-03-10 2012-11-14 Nestec S.A. Ácidos dicarboxílicos de cadena mediana y sus derivados y trastornos metabólicos
JP2011520890A (ja) * 2008-05-15 2011-07-21 メルク・シャープ・エンド・ドーム・コーポレイション オキサゾロベンゾイミダゾール誘導体
WO2010072386A2 (en) 2008-12-23 2010-07-01 Roche Diagnostics Gmbh Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof
CN102292074B (zh) * 2009-01-23 2013-08-21 霍夫曼-拉罗奇有限公司 包含阿格列扎的药物组合物
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) * 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
EP2585452B1 (en) 2009-12-07 2015-09-23 F.Hoffmann-La Roche Ag Process for the preparation of propionic acid derivatives
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
CA2879500A1 (en) * 2012-09-12 2014-03-20 F. Hoffmann-La Roche Ag Solid forms of (s)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid and of salts thereof
CN109588042A (zh) 2015-11-18 2019-04-05 豪夫迈·罗氏有限公司 用于治疗糖尿病肾病的阿格列扎
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
EP4384507A4 (en) * 2021-08-13 2025-06-18 Alebund Pharmaceuticals (Hong Kong) Limited Deuterated compounds
EP4615433A1 (en) 2022-11-08 2025-09-17 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2032677C1 (ru) * 1992-05-05 1995-04-10 Бристоль-Мейерз Сквибб Компани Производные оксазола
SK695A3 (en) 1992-07-03 1995-07-11 Smithkline Beecham Plc Heterocyclic compounds method of their production and using
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
KR100499106B1 (ko) 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
DE19711616A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
ES2200248T3 (es) 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
DK1313716T3 (da) * 2000-08-23 2007-08-27 Lilly Co Eli Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister
RU2278859C2 (ru) * 2001-05-15 2006-06-27 Ф.Хоффманн-Ля Рош Аг Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета

Also Published As

Publication number Publication date
KR20030096397A (ko) 2003-12-24
RU2003134150A (ru) 2005-06-10
WO2002092084A1 (en) 2002-11-21
SK287842B6 (sk) 2011-12-05
JP4330883B2 (ja) 2009-09-16
DE60211891T2 (de) 2007-05-24
EP1392295B1 (en) 2006-05-31
JO2282B1 (en) 2005-09-12
NO20035086L (no) 2003-11-14
HK1067534A1 (en) 2005-04-15
BG108362A (bg) 2005-03-31
CZ20033037A3 (cs) 2004-06-16
EG25755A (en) 2012-06-26
PL208074B1 (pl) 2011-03-31
HUP0400992A3 (en) 2007-11-28
PA8544901A1 (es) 2003-01-24
HUP0400992A2 (hu) 2004-08-30
IL158589A0 (en) 2004-05-12
HU230224B1 (hu) 2015-10-28
NO20035086D0 (no) 2003-11-14
CA2445145C (en) 2008-10-14
IL158589A (en) 2010-11-30
SK13852003A3 (en) 2004-10-05
HRP20030889A2 (en) 2005-08-31
AU2002342244B2 (en) 2005-06-16
ATE327753T1 (de) 2006-06-15
ME01310B (me) 2011-10-10
MY136761A (en) 2008-11-28
DK1392295T3 (da) 2006-10-02
CY1105160T1 (el) 2009-11-04
SI1392295T1 (sl) 2006-10-31
US6642389B2 (en) 2003-11-04
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
DE60211891D1 (de) 2006-07-06
BR0209821A (pt) 2004-06-01
HRP20030889B1 (hr) 2011-10-31
PT1392295E (pt) 2006-09-29
CA2445145A1 (en) 2002-11-21
EP1392295A1 (en) 2004-03-03
KR100654516B1 (ko) 2006-12-05
CN1509173A (zh) 2004-06-30
NZ529033A (en) 2005-06-24
GT200200085A (es) 2003-01-16
JP2009138011A (ja) 2009-06-25
JP2004529174A (ja) 2004-09-24
BG66316B1 (bg) 2013-04-30
ZA200308538B (en) 2005-04-26
ES2264482T3 (es) 2007-01-01
AR035892A1 (es) 2004-07-21
CN100356917C (zh) 2007-12-26
US20030055265A1 (en) 2003-03-20
NO333833B1 (no) 2013-09-30
PE20021152A1 (es) 2003-02-07
BRPI0209821B1 (pt) 2016-09-27
MXPA03010435A (es) 2004-03-09
MA27025A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
PA8544901A1 (es) Derivados de oxazol
UY28892A1 (es) Inhibidores selectivos de la enzima dipeptidilpeptidasa-iv (dpp-iv) composiciones farmaceuticas de las mismas y su uso terapeutico
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
ECSP045193A (es) "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas"
UY27388A1 (es) Nuevos compuestos
ECSP10010178A (es) Derivados bis-(sulfonilamino) en terapia 066
PE20011314A1 (es) DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA
PE20061153A1 (es) Compuestos heterociclicos como inhibidores del factor viia
ECSP093680A (es) Proceso para derivados del acido fenilacetico
SV2003001099A (es) Nuevos derivados de acido sulfonico ref.pc23084
PA8581201A1 (es) Nuevos derivados de tiazol
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
UY26847A1 (es) Derivados de la pirrolidina
NO20082181L (no) Formuleringer av Fispemifen
UY27975A1 (es) Derivados de indolilo
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
AR016382A1 (es) Uso de un derivado del acido bencil-indazol metoxialcanoico.
UY26846A1 (es) Derivados de la pirrolidina
HN2003000015A (es) Sales estables del acido o acetilsalicilico con aminoacidos basicos i i.
PE20040916A1 (es) Diamidas de acido pirimidin-4,6-dicarboxilico como inhibidores selectivos de mmp-13
ES2190985T3 (es) Tratamiento de migraña por administracion de acido alfa-lipoico o de derivados del mismo.
PE20011260A1 (es) Derivados de sulfonamida
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-